Login to Your Account



Epilepsy trial shakes faith in Zynerba's lead CBD candidate

By Michael Fitzhugh
Staff Writer

Monday, August 7, 2017

Zynerba Pharmaceuticals Inc. shares (NASDAQ:ZYNE) plunged more than 55 percent Monday to $6.67 on news that its lead candidate, the cannabidiol (CBD) gel ZYN-002, missed the primary endpoint of a phase II trial, failing to help adult epilepsy patients with focal seizures achieve a statistically significant reduction in seizures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription